Evidence map›Paper›PMID 41743709›Full record

ArticleFrontiers in immunology2026

A novel oral immunotherapy strategy using transgenic barley induces

Fenja Johanna von der Höden, Sara Björk Stefansdottir, Sigurbjörg Torsteinsdottir, Vilhjalmur Svansson, Jon Mar Björnsson, Bettina Wagner, Dorontina Mahmuti, Eliane Marti, Sigridur Jonsdottir

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fenja Johanna von der HödenInstitute for Experimental Pathology, Biomedical Center, University of Iceland, Keldur, Reykjavik, Iceland.
Sara Björk StefansdottirInstitute for Experimental Pathology, Biomedical Center, University of Iceland, Keldur, Reykjavik, Iceland.
Sigurbjörg TorsteinsdottirInstitute for Experimental Pathology, Biomedical Center, University of Iceland, Keldur, Reykjavik, Iceland.
Vilhjalmur SvanssonInstitute for Experimental Pathology, Biomedical Center, University of Iceland, Keldur, Reykjavik, Iceland.
Jon Mar BjörnssonORF Genetics, Kópavogur, Iceland.
Bettina WagnerDepartment of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States.
Dorontina MahmutiClinical Immunology Group, Division of Neurological Science, Department of Clinical Research-Veterinary Public Health (VPH), Vetsuisse Faculty, University of Bern, Bern, Switzerland.
Eliane MartiClinical Immunology Group, Division of Neurological Science, Department of Clinical Research-Veterinary Public Health (VPH), Vetsuisse Faculty, University of Bern, Bern, Switzerland.
Sigridur JonsdottirInstitute for Experimental Pathology, Biomedical Center, University of Iceland, Keldur, Reykjavik, Iceland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Insect bite hypersensitivity (IBH) is a seasonal, IgE-mediated allergic dermatitis of horses caused by salivary gland proteins of biting midges ( Methods: Twelve naïve Icelandic horses were randomized into treatment (n=6) and control (n=6) groups. The treatment group received 11.44 g of the major Results: Four of six treated horses produced Cul o 2p-specific IgG1, IgG4/7, and IgA in both serum and saliva. The induced antibodies could partly inhibit IgE binding. Elevated secretion of IFN-γ and IL-10 but no IL-4 secretion was observed in supernatants of re-stimulated PBMCs in treated horses compared to controls, reaching statistical significance for IFN-γ. No Cul o 2p-specific IgE was detected, and no adverse clinical reactions occurred during treatment. Conclusion: The feed-based approach using transgenic barley paste induced Cul o 2p-specific humoral and cellular immune responses in naïve horses, supporting its potential as a scalable and field-feasible platform for prophylactic and therapeutic applications in IBH. Clinical trials in IBH-affected horses are warranted to assess efficacy.

Indexed as

AllergensCeratopogonidaeDesensitization, ImmunologicHordeumHorse DiseasesInsect Bites and StingsInsect ProteinsPlants, Genetically ModifiedAdministration, OralAnimalsCytokinesFemaleHorsesImmunoglobulin EImmunoglobulin GVenom HypersensitivityAllergensCytokinesImmunoglobulin EImmunoglobulin GInsect ProteinsallergyCulicoides midgeshorse (Equus caballus)insect bite hypersensitivityoral immunotherapy (OIT)transgenic barley

Identifiers

PMID41743709
PMCPMC12930272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.